רווח למניה בשנים עשר החודשים האחרונים: Processa Pharma (PCSA)
Outsourcing development and testing to external contractors creates operational dependency, and the rolling annual earnings per share chart on GURU.Markets is available for analysis, where -5.62 serves as the current metric level. A stable staff of oncologists and the potential of the high-margin PCS platform upon FDA approval allow Processa Pharmaceuticals (PCSA) to effectively scale its business in the breast cancer treatment sector.
פילוחים אנליטיים של חברת Processa Pharmaceuticals Inc. (PCSA)
Annual net earnings per share measure the actual portion of income attributable to a single security. This indicator separates actual business efficiency from market hype. By analyzing the 12-month EPS history, an investor can see the objective dynamics of capitalization. For Processa Pharmaceuticals (PCSA), this trend reflects the development cost of the CAP7 platform. Growth in this metric would confirm the successful scaling of the oncology pipeline.
